局部JTE-052(Janus激酶抑制剂)治疗日本中重度特应性皮炎II期随机对照研究
BACKGROUND: JTE-052 is a novel Janus kinase inhibitor presently under clinical development for the topical treatment of atopic dermatitis (AD). OBJECTIVES: To evaluate the efficacy and safety of JTE-052 ointment in Japanese adult patients with AD.…
要点
- 瘙痒NRS评分最早在治疗第1天夜间即出现显著改善。
核心结论
- 局部JTE-052可显著且快速改善日本中重度特应性皮炎成人患者的临床体征与症状,安全性良好,是潜在治疗选择。
研究设计与样本
- II期、多中心、随机、赋形剂对照临床研究,纳入327例日本中重度特应性皮炎成人患者。
主要发现
- JTE-052组在其他参数上也显示显著改善,瘙痒NRS评分最早在第1天夜间即降低。
- JTE-052软膏最高至3%浓度安全且耐受性良好。
关键数值与推荐
- 主要疗效终点为治疗结束时mEASI评分较基线的百分比变化。
- 次要疗效终点包括瘙痒NRS评分较基线的变化。
临床怎么用
- 对于中重度特应性皮炎成人患者,局部JTE-052每日两次外用4周可显著改善皮损和瘙痒。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: JTE-052 is a novel Janus kinase inhibitor presently under clinical development for the topical treatment of atopic dermatitis (AD). OBJECTIVES: To evaluate the efficacy and safety of JTE-052 ointment in Japanese adult patients with AD. METHODS: Patients with moderate-to-severe AD were randomized (2: 2: 2: 2: 1: 1) to receive JTE-052 ointment at 0·25%, 0·5%, 1% or 3%, the vehicle ointment or tacrolimus 0·1% ointment (reference) twice daily for 4 weeks. The primary efficacy end point was the percentage change in modified Eczema Area Severity Index (mEASI) score from baseline at the end of treatment (EOT). Secondary efficacy end points included change from baseline in the pruritus numerical rating scale (NRS) score. RESULTS: In total, 327 patients were enrolled. At EOT, the least-squares mean percentage changes from baseline in mEASI score for JTE-052 at 0·25%, 0·5%, 1% and 3% and the vehicle ointment were -41·7%, -57·1%, -54·9%, -72·9% and -12·2%, respectively. All JTE-052 groups showed significant reductions of mEASI score vs. the vehicle group (P < 0·001 for all). In the tacrolimus group, the mean percentage change in mEASI score was -62·0%. The JTE-052 groups also showed significant improvement in other parameters; notably, the pruritus NRS score was reduced as early as day 1 night-time. JTE-052 ointment at doses up to 3% was safe and well tolerated. CONCLUSIONS: Topical JTE-052 markedly and rapidly improved clinical signs and symptoms in Japanese adult patients with moderate-to-severe AD, with a favourable safety profile. The study results indicate that topical JTE-052 is a promising therapeutic option for AD. The trial registration number is JapicCTI-152887.
引用
- Nakagawa H, Nemoto O, Igarashi A, et al. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol. 2018. PMID: 28960254. doi:10.1111/bjd.16014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。